{
    "pmcid": "9219022",
    "summary": "The paper titled \"Production and purification of shark and camel single domain antibodies from bacterial and mammalian cell expression systems\" provides a comprehensive guide on the production, purification, and validation of single domain antibodies, specifically focusing on shark VNARs and camelid VHHs, commonly known as nanobodies. These antibodies are particularly relevant for designing SARS-CoV-2 nanobody binders due to their unique properties and potential therapeutic applications.\n\n### Key Insights on Nanobodies:\n\n1. **Structure and Characteristics**:\n   - Nanobodies are the smallest antigen recognition domains (~15 kDa) derived from camelids (VHH) and sharks (VNAR).\n   - They possess unique structural features, including extended complementarity determining regions (CDRs), allowing them to bind to concave and hidden epitopes inaccessible to conventional antibodies.\n   - Their small size, high stability across various pH and temperature ranges, and strong binding affinities make them ideal for targeting viral proteins like the SARS-CoV-2 spike protein.\n\n2. **Advantages for SARS-CoV-2 Applications**:\n   - Nanobodies can be nebulized for direct delivery into the lungs, offering a potential therapeutic route for respiratory viruses such as SARS-CoV-2.\n   - They can be humanized to reduce immunogenicity, making them suitable for clinical applications.\n\n3. **Expression Systems**:\n   - Nanobodies can be expressed in bacterial (e.g., E. coli) and mammalian systems, each offering distinct advantages.\n   - Bacterial systems are cost-effective and suitable for large-scale production, while mammalian systems provide post-translational modifications, such as glycosylation, which can be crucial for certain therapeutic applications.\n\n4. **Production and Purification Protocols**:\n   - The paper details protocols for expressing nanobodies in E. coli using phagemid vectors and in mammalian cells using pcDNA3.1 vectors.\n   - Purification involves immobilized metal affinity chromatography (IMAC) using His-tagged proteins, with specific protocols for both large-scale and small-scale production.\n   - The use of polymyxin B for bacterial cell lysis is highlighted as a critical step for efficient protein release from the periplasm.\n\n5. **Validation and Characterization**:\n   - The functionality of purified nanobodies is validated using ELISA, where binding to the SARS-CoV-2 spike protein is assessed.\n   - The presence of a Flag tag allows for easy detection and validation of binding activity.\n\n6. **Yield and Efficiency**:\n   - The yield of nanobodies varies depending on the expression system and specific nanobody, with shark VNARs yielding 2 to 15 mg/L and camel VHHs yielding 5 to 40 mg/L.\n   - The paper provides detailed troubleshooting tips to optimize yield and purity, emphasizing the importance of signal peptides and transfection efficiency in mammalian systems.\n\n7. **Potential for Therapeutic Applications**:\n   - Nanobodies' ability to bind unique epitopes and their stability make them promising candidates for therapeutic applications, including antibody-drug conjugates and chimeric antigen receptor (CAR) therapies.\n   - Their modular nature allows for the creation of multi-domain constructs, enhancing their versatility in drug design.\n\nOverall, the paper serves as a valuable resource for researchers aiming to develop nanobody-based therapeutics against SARS-CoV-2, providing detailed methodologies and insights into optimizing production and purification processes.",
    "title": "Production and purification of shark and camel single domain antibodies from bacterial and mammalian cell expression systems"
}